With 2.45 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.57 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $32.49 whereas the lowest price it dropped to was $18.55. The 52-week range on XCUR shows that it touched its highest point at $19.62 and its lowest point at $1.44 during that stretch. It currently has a 1-year price target of $10.00. Beta for the stock currently stands at 2.32.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of XCUR was up-trending over the past week, with a rise of 578.68%, but this was up by 1028.27% over a month. Three-month performance surged to 1598.32% while six-month performance rose 1384.73%. The stock gained 969.39% in the past year, while it has gained 821.59% so far this year.
Float and Shares Shorts:
At present, 1.73 million XCUR shares are outstanding with a float of 0.83 million shares on hand for trading. On 2024-10-31, short shares totaled 31088.0, which was 143.0 higher than short shares on 1727654400. In addition to Mr. Paul Kang as the firm’s CEO, President & Director, Ms. Jiyoung Hwang serves as its CFO, Secretary & Director.
Institutional Ownership:
Through their ownership of 0.04287 of XCUR’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, XCUR reported revenue of $0.0 and operating income of -$1434000.0. The EBITDA in the recently reported quarter was $275000.0 and diluted EPS was -$0.57.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
Analysts have provided yearly estimates in a range of -$111 being high and -$111 being low. For XCUR, this leads to a yearly average estimate of -$111. The surprise factor in the prior quarter was -$10.5. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
